Quick Answer
Xeris Biopharma Holdings, Inc. reported Total Revenue of $291.85 million for the year ending 2025.
- Xeris Biopharma Holdings, Inc. showed an increase of +43.7% in Total Revenue from 2024 to 2025.
- This data is from Xeris Biopharma Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2020 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $9.40 million | Q1 2021: $8.20 million | Q1 2021: $8.05 million | Q2 2021: $8.91 million | Q3 2021: $11.06 million | Q1 2022: $22.07 million | Q1 2022: $22.07 million | Q2 2022: $25.31 million | Q3 2022: $29.73 million | Q1 2023: $33.20 million | Q2 2023: $38.01 million | Q3 2023: $48.32 million | Q1 2024: $40.64 million | Q2 2024: $48.07 million | Q3 2024: $54.27 million | Q1 2025: $60.12 million | Q2 2025: $71.54 million | Q3 2025: $74.38 million.
- Over the full 8 years of available data (2020 to 2025), Xeris Biopharma Holdings, Inc.'s Total Revenue has grown by 1,348.0%.
- Historical annual values: Fiscal year 2025: $291.85 million | Fiscal year 2024: $203.07 million | Fiscal year 2023: $163.91 million | Fiscal year 2022: $110.25 million | Fiscal year 2021: $49.59 million | Fiscal year 2021: $49.59 million | Fiscal year 2020: $20.44 million | Fiscal year 2020: $20.16 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: